Quotes 5-day view Delayed Nse India Stock Exchange
01/12/2021
01/13/2021
01/14/2021
01/15/2021
01/18/2021
Date
843.15(c)
841.7(c)
840.9(c)
823.7(c)
801.75 Last
4 338 010
3 596 529
3 652 930
3 137 877
3 742 440 Volume
-1.60% -0.17% -0.10% -2.05% -2.66% Change
Sales 2021
192 B 2 617 M 2 617 M
Net income 2021
24 111 M 329 M 329 M
Net Debt 2021
3 392 M 46,3 M 46,3 M
P/E ratio 2021
27,7x
Yield 2021
0,47%
Sales 2022
208 B 2 841 M 2 841 M
Net income 2022
26 505 M 362 M 362 M
Net cash position 2022
15 930 M 218 M 218 M
P/E ratio 2022
24,9x
Yield 2022
0,54%
Capitalization
664 B 9 081 M 9 075 M
EV / Sales 2021
3,49x
EV / Sales 2022
3,12x
Nbr of Employees
25 845
Free-Float
61,5%
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products.
Net sales by source of income break down between sale of products (96.9%) and...
Notations Surperformance© of Cipla Limited
Trading Rating : Investor Rating :
All news about CIPLA LIMITED
News in other languages on CIPLA LIMITED
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends CIPLA LIMITED
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
32
Average target price
916,90 INR
Last Close Price
823,70 INR
Spread / Highest target
26,3%
Spread / Average Target
11,3%
Spread / Lowest Target
-12,6%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
